Lead Product(s) : Alvocidib,Cytarabine,Mitoxantrone
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Updated findings from the Phase 1, dose-escalation, safety and biomarker study of alvocidib followed by cytarabine and daunorubicin (7+3) induction therapy showed encouraging clinical activity and a tolerable safety profile in adults with newly diagnosed...
Product Name : DSP-2033
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 06, 2020
Lead Product(s) : Alvocidib,Cytarabine,Mitoxantrone
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alvocidib,Cytarabine,Mitoxantrone
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zella 201 is a biomarker-driven study of alvocidib followed by cytarabine and mitoxantrone in patients with relapsed/refractory MCL-1 dependent acute myeloid leukemia. Data presented will include findings from an exploratory cohort of newly diagnosed, hi...
Product Name : Flavopiridol
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 11, 2020
Lead Product(s) : Alvocidib,Cytarabine,Mitoxantrone
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alvocidib,Decitabine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : First patient has been dosed with a one-hour dosing schedule for investigational agent alvocidib, a potent CDK9 inhibitor, administered in sequence after azacitidine, in the expansion of the Phase 1b/2 Zella 102 study in patients with myelodysplastic syn...
Product Name : DSP-2033
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 14, 2020
Lead Product(s) : Alvocidib,Decitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alvocidib,Cytarabine,Mitoxantrone
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The open-label, randomized study has two parts and will evaluate the safety and efficacy of alvocidib in monotherapy or in combination with low-dose cytarabine.
Product Name : DSP-2033
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 15, 2020
Lead Product(s) : Alvocidib,Cytarabine,Mitoxantrone
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable